4-Azaindoles as Inhibitors of p38 MAP Kinase
J ournal of Medicinal Chemistry, 2003, Vol. 46, No. 22 4713
(2) (a) Schett, G.; Tohidast-Akrad, M.; Smolen, J . S.; Schmid, B. J .;
Steiner, C.; Bitzan, P.; Zenz, P.; Redlich, K.; Xu, Q.; Steiner, G.
Activation, differential localization, and regulation of the stress-
activated protein kinases, extracellular signal-regulated kinase,
c-J un N-terminal kinase, and p38 mitogen-activated protein
kinase, in synovial tissue and cells in rheumatoid arthritis.
Arthritis Rheum. 2000, 43, 2501-2512. (b) Foster, M. L.; Halley,
F.; Souness, J . E. Potential of p38 inhibitors in the treatment of
rheumatoid arthritis. Drug News Perspect. 2000, 13, 488-497.
(3) (a) J ones R E.; Moreland, L. W. Tumor necrosis factor inhibitors
for rheumatoid arthritis. Bull. Rheum. Dis. 1999, 48, 1-4. (b)
Tumor Necrosis Factor Antagonists as Potential Treatments in
Rheumatoid Arthritis. A CME Satellite Symposium at the
American College of Rheumatology Annual Meeting, held 12
November 1998, in San Diego, California. J . Rheum. Suppl.
1999, 57. (c) Hommes, D.; van Den Blink, B.; Plasse, T.;
Bartelsman J .; Cuiping, X.; Macpherson, B.; Tytgat, G.; Peppe-
lenbosch, M.; Van Deventer, S. Inhibition of stress-activated
MAP kinases induces clinical improvement in moderate to severe
Crohn’s disease. Gastroenterology 2002, 122, 7-14.
(4) (a) Lee, J . C.; Kumar, S.; Griswold, D. E.; Underwood, D. C.;
Votta, B. J .; Adams, J . L. Inhibition of p38 MAP kinase as a
therapeutic strategy. Immunopharmacology 2000, 47, 185-201.
(b) Boehm, J . C.; Adams, J . L. New inhibitors of p38 kinase.
Expert Opin. Ther. Pat. 2000, 10, 25-37. (c) Mclay, L. M.; Halley,
F.; Souness, J . E.; McKenna, J .; Benning, V.; Birrell, M.; Burton,
B.; Belvisi, M.; Collis, A.; Constan, A.; Foster, M.; Hele, D.;
J ayyosi, Z.; Kelley, M.; Maslen, C.; Miller, G.; Ouldelhkim, M.
C.; Page, K.; Phipps, S.; Pollock, K.; Porter, B.; Ratcliffe, A. J .;
Redford, E. J .; Webber, S.; Slater, B.; Thybaud, V.; Wilsher, N.
The discovery of RPR 200765A, a p38 MAP kinase inhibitor
displaying a good oral antiarthritic efficacy. Bioorg. Med. Chem.
2001, 9, 537-54. (d) Wadsworth, S. A.; Cavender, D. E.; Beers,
S. A.; Lalan, P.; Schafer, P. H.; Malloy, E. A.; Wu, W.; Fahmy,
B.; Olini, G. C.; Davis, J . E.; Pellegrino-Gensey, J . L.; Wachter,
M. P.; Siekierka, J . J . RWJ 67657, a potent, orally active
inhibitor of p38 mitogen-activated protein kinase. J . Pharm. Exp.
Ther. 1999, 291, 680-687. (e) Dumas, J .; Sibley, R.; Riedl, B.;
Monahan, M. K.; Lee, W.; Lowinger, T. B.; Redman, A. M.;
J ohnson, J . S.; Kingery-Wood, J .; Scott, W. J .; Smith, R. A.;
Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J .;
Bhargava, A.; Wilhelm, S. M.; Shrikhande, A Discovery of a new
class of p38 kinase inhibitors. Bioorg. Med. Chem. Lett. 2000,
10, 2047-2050. (f) Feldmann, M.; Brennan, F. M.; Maini, R. N.
Potential of p38 inhibitors in the treatment of rheumatoid
arthritis. Annu. Rev. Immunol. 1996, 14, 397-440.
(5) (a) Boehm, J . C.; Smietana, J . M.; Sorenson, M. E.; Garigipati,
R. S.; Gallagher, T. F.; Sheldrake, P. L.; Bradbeer, J .; Badger,
A. M.; Laydon, J . T.; et al. 1-Substituted 4-Aryl-5-pyridinylimi-
dazoles: A New Class of Cytokine Suppressive Drugs with Low
5-Lipoxygenase and Cyclooxygenase Inhibitory Potency. J . Med.
Chem. 1996, 39, 3929-3937. (b) Gallagher, T. F.; Seibel, G. L.;
Kassis, S.; Laydon, J . T.; Blumenthal, M. J .; Lee, .J C.; Lee, D.;
Boehm, J ., C.; Fier-Thompson, S. M.; Abt, J . W.; Soreson, M.
E.; Smietana, J . M.; Hall, R. F.; Garigipati, R. S; Bender, P. E;
Erhard, K. F; Krog, A. J .; Hofmann, G. A.; Sheldrake, P. L.;
McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J . L.
Regulation of stress-induced cytokine production by pyridi-
nylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem.
1997, 5, 49-64. (c). Liverton, N. J .; Butcher, J . W.; Claiborne,
C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger,
S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J . P.;
Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J .; Fletcher,
D. S.; Frantz, B.; Hanlon, W. A.; Harper, C.l F.; Hofsess, S. J .;
Kostura, M.; Lin, J .; Luell, S.; O’Neill, E. A.; Orevillo, C. J .; Pang,
M.t; Parsons, J .; Rolando, A.; Sahly, Yousif; V., Denise M.;
O’Keefe, S. J . Design and Synthesis of Potent, Selective, and
Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38
Mitogen-Activated Protein Kinase. J . Med. Chem. 1999, 42,
2180-2190. (d) Perregaux, D. G.; Dean, D.; Cronan, M.; Con-
nelly, P.; Gabel, C. A Inhibition of interleukin-1 beta production
by SKF86002: evidence of two sites of in vitro activity and of a
time and system dependence. Mol. Pharm. 1995, 48, 433-42.
(e) Pier, C.; Pargellis, C.; Regan, J . The Non-Diaryl Heterocycle
Classes of p38 MAP Kinase Inhibitors. Curr. Top. Med. Chem.
2002, 2, 1021-1035. (e) J ackson, P. F.; Bullington, J . L.
Pyridinylimidazole Based p38 MAP Kinase Inhibitors. Curr. Top.
Med. Chem. 2002, 2, 1011-1020.
S. A.; Huddleston, M. J .; Seibel, G.; Porter, T. G.; Livi, G. P.;
Adams, J . L.; Lee, J . C. Pyridinyl Imidazole Inhibitors of p38
Mitogen-Activated Protein Kinase Bind in the ATP Site. J . Biol.
Chem. 1997, 272, 12116-12121.
(8) Boehm, J . C.; Adams, J . L. New Inhibitors of p38 Kinase. Expert
Opin. Ther. Pat. 2000, 10, 25-37.
(9) Lee, J . C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J . L. P38
Mitogen-Activated Protein Kinase Inhibitor- Mechanisms and
Therapeutic Potentials. Pharmacol. Ther. 1999, 82, 389-397.
(10) Wang, Z.; Canagarajah, B. J .; Boehm, J . C.; Kassisa, S.; Cobb,
M. H.; Young, P.lR.; Abdel-Meguid, S.; Adams, J . L.; Goldsmith,
E. J . Structural Basis of Inhibitor Selectivity in MAP Kinases.
Structure 1998, 6, 1117-1128.
(11) (a) Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes,
W.; Veal, J .; Kuyper, L. F. Binding Mode of the 4-Anilino-
quinazoline Class of Protein Kinase Inhibitor: X-ray Crystal-
lographic Studies of 4-Anilinoquinazoline Bound to Cyclin-
Dependent Kinase 2 and p38 Kinase. J . Med. Chem. 2000, 43,
133-138. (b) Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.;
Leost, M.; Ceballos-Picot, I.; Noble, M.; Endicott, J .; Vierfont,
J .; Meijer, L. Aloisines, a New Family of CDK/GSK-3 Inhibitors.
SAR Study, Crystal Structure in Complex with CDK2, Enzyme
Selectivity, and Cellular Effects. J . Med. Chem. 2003, 46, 222-
236.
(12) 7. Chen, C.; Lieberman, D. R.; Larsen, R. D.; Verhoeven, T. R.;
Reider, P.l J . Syntheses of Indoles via a Palladium-Catalyzed
Annulation between Iodoanilines and Ketones. J . Org. Chem.
1997, 62, 2676-2677.
(13) Turner, J . A. Regiospecific Electrophilic Substitution of Ami-
nopyridines: Ortho Lithiation of 2-, 3-, and 4-(Pivaloylamino)
pyridines. J . Org. Chem. 1983, 48, 3401-8.
(14) (a) Fustner, A.; Hupperts, A.; Ptock, A.; J anssen, E. “Site
Selective” Formation of Low-Valent Titanium Reagents: An
“Instant” Procedure for the Reductive Coupling of Oxo Amides
to Indoles. J . Org. Chem. 1994, 59, 5215-29. (b) Fuerstner, A.;
Ernst, A.; Krause, H.; Ptock, A. Low-valent titanium induced
indole formation: syntheses of secofascaplysin, indolopyri-
docoline and an endothelin-receptor-antagonist. Tetrahedron
1996, 52, 7329-7344.
(15) Robinson B., Eds. The Fisher Indole Synthesis; J ohn Wiley &
Sons: Chichester, 1982; pp 48-59.
(16) Chan, S.; et al., unpublished results (manuscript in preparation).
(17) (a) Mann, G.; Hartwig, J . F.; Driver, M. S.; Ferna´ndez-Rivas, C.
J . Am. Chem. Soc. 1998, 120, 827-828. (b) Wagaw, S.; Yang, B.
H.; Buchwald, S. L. A palladium-catalysed Strategy for the
preparation of indoles. A novel entry into the fisher indole
synthesis. J . Am. Chem. Soc. 1998, 120, 6621-6622.
(18) Barlin, G. B.; Davies, L. P.; Ireland, S. J .; Ngu, M. M. L. Imidazo-
[1,2-b] pyridazines. VI. Synthesis and central nervous system
activities of some 6-(alkoxy-and methylthio-phenoxy and meth-
oxy-2-phenyl (substituted phenyl and pyridinyl) imidazo [1,2-b]
pyridazines. Aust. J . Chem. 1989, 42, 1735-1748.
(19) Mu¨ller, C. E.; Hide, I.; Daly, J . W.; Rothenha¨usler, K.; Eger, K.
7-Deaza-2-phenyladenines: structure activity relationships of
potent A1 Selective adenosine receptor antagonists. J . Med.
Chem. 1990, 33, 2822-2828.
(20) Greene, T. W.; Wuts, P. G. M., Eds. Protective Groups in Organic
Synthesis; J ohn Wiley & Sons: New York, 1991; pp 77-83.
(21) Shiotani, S.; Morita, H. Furopyridines III a New Synthesis of
Furo[3,2-b]pyridine. J . Heterocycl. Chem. 1986, 23, 665-668.
(22) Tanaka, S. Coumarones from ï-hydroxy aldehydes and bromo-
malonic ester. J . Am. Chem. Soc. 1951, 73, 872.
(23) Solberg, J .; Undheim, K. Regiochemistry in Pd-catalysed orga-
notin reactions with halopyrimidines. Acta Chem. Scand. 1989,
43, 62-68.
(24) Stille, J . K. Angew. Chem., Int. Ed. Engl. 1986, 25, 508.
(25) Coperet, C.; Adolfsson, H.; Chiang, J . P.; Yudin, A. K.; Sharpless,
K. B. A simple and efficient method for the preparation of
pyridine-N-oxides II. Tetrahedron Lett. 1998, 39, 761-764.
(26) Sheldrake, P. W. The Anion of 4-Dimethoxymethylpyridine. A
convenient synthesis of some 4-pyridyl ketones. Synth. Commun.
1993, 23, 1967-1971.
(27) p38 R and p38 â isoforms are inhibited by compound 9 with IC50’s
of 6.5 nM and 150 nM, respectively. P38 γ and δ are not inhibited
at concentrations up to 100 µM.
(28) Brunger A. T. Xplor: Version 3.1; Yale Press: New Haven, 1987.
(b) Murshudov, G. N.; Vagin, A. A.; Dodson, E. J . Refinement of
macromolecular structures by the maximum-liklihood method.
Acta Crystallogr. 1997, D53, 240-255.
(6) J ackson, P. F.; Bullington, J . L. Pyridinylimidazole Based p38
MAP Kinase Inhibitors. Curr. Top. Med. Chem. 2002, 2, 1011-
1020.
(7) Tong, L.; Pav, S.; White, D.; Rogers, S.; Crane, K.; Cywin, C. A.
Highly Specific Inhibitor of Human p38 MAP Kinase Binds in
the ATP Pocket. Nat. Struct. Biol. 1997, 4, 311-316. Young, P.
R.; McLaughlin, M.; Kumar, S.; Kassis, S.; Doyle, M. L.;
McNulty, D.; Gallagher, T. F.; Fisher, S.; McDonnell, P. C.; Carr,
(29) Berman, H. M.; Westbrook, J .; Feng, Z.; Gilliland, G.; Bhat, T.
N.; Weissig, H.; Shindyalov, I. N.; Bourne P. E. The Protein Data
Bank. Nucleic Acid Res. 2000, 28, 235-242.
(30) Reimund, J . M., et al. Gut 1996, 39, 684-689.
J M0301787